Prognosis
Astra, Glaxo Join Rush Back to Lab to Target Covid Variants
- Astra-Oxford team plans new version of its vaccine by fall
- GSK and CureVac join forces for next-generation mRNA shot
This article is for subscribers only.
AstraZeneca Plc and GlaxoSmithKline Plc joined the rush to develop a new generation of vaccines against emerging variants of the coronavirus that could make the first shots less effective.
AstraZeneca and the University of Oxford are planning to have a shot available by the fall, in time for the next round of immunizations that may be required before winter. U.K. rival Glaxo and Germany’s CureVac NV teamed up to create next-generation messenger RNA vaccines to combat new strains.